Pharming (PHAR) Long-Term Deferred Tax (2019 - 2026)

Pharming's Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• Quarterly Long-Term Deferred Tax rose 66.76% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 66.76% YoY) and the FY2025 annual result came in at $31.0 million, up 1.55% from the prior year.
• Long-Term Deferred Tax was $30.7 million for Q1 2026 at Pharming, down from $31.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $39.0 million in Q2 2024 and bottomed at $21187.0 in Q3 2022.
• A 5-year average of $26.8 million and a median of $29.4 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax sank 99.9% — and 2023, when it soared 125486.44%.
• Pharming's Long-Term Deferred Tax stood at $23.0 million in 2022, then increased by 29.55% to $29.8 million in 2023, then gained by 2.63% to $30.5 million in 2024, then gained by 1.55% to $31.0 million in 2025, then declined by 1.13% to $30.7 million in 2026.
• Business Quant data shows PHAR's Long-Term Deferred Tax at $30.7 million in Q1 2026, $31.0 million in Q4 2025, and $27.5 million in Q3 2025.